Evidence map›Paper›PMID 31187425›Full record

ArticleInternational urology and nephrology2019

Dialysate copeptin and peritoneal transport in incident peritoneal dialysis patients.

Maciej Fijałkowski, Krzysztof Safranow, Bengt Lindholm, Kazimierz Ciechanowski, Anna Maria Muraszko, Barbara Dołęgowska, Katarzyna Dołęgowska, Edyta Golembiewska

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International urology and nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Maciej FijałkowskiDepartment of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, Al. Powstancow Wielkopolskich 72, 70-111, Szczecin, Poland.
Krzysztof SafranowDepartment of Biochemistry and Medical Chemistry, Pomeranian Medical University, Szczecin, Poland.
Bengt LindholmDivision of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Campus Flemingsberg, Stockholm, Sweden.
Kazimierz CiechanowskiDepartment of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, Al. Powstancow Wielkopolskich 72, 70-111, Szczecin, Poland.
Anna Maria MuraszkoDepartment of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, Al. Powstancow Wielkopolskich 72, 70-111, Szczecin, Poland.
Barbara DołęgowskaDepartment of Laboratory Diagnostics and Molecular Medicine, Pomeranian Medical University, Szczecin, Poland.
Katarzyna DołęgowskaDepartment of Laboratory Diagnostics and Molecular Medicine, Pomeranian Medical University, Szczecin, Poland.
Edyta GolembiewskaDepartment of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, Al. Powstancow Wielkopolskich 72, 70-111, Szczecin, Poland. egsunshine72@gmail.com.ORCID http://orcid.org/0000-0001-6461-1570
Pomeranian Medical University · PLKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSystemic and intraperitoneal inflammation are characteristic features of patients with end-stage renal disease undergoing chronic peritoneal dialysis (PD). Arginine vasopressin (AVP) and its surrogate marker copeptin play important roles in many pathophysiological processes in chronic kidney disease. The aim of this study was to assess if copeptin concentrations in plasma and dialysate were related to peritoneal transport parameters and residual renal function (RRF) in incident PD patients.

methodsIn 37 clinically stable incident PD patients (mean age 50 years, 68% women, 32% diabetes), a 4 h peritoneal equilibration test (PET) was performed 4-6 weeks after the onset of PD. Plasma (at 2 h of PET) and dialysate (at 4 h) concentrations of copeptin, high-sensitivity C-reactive protein and interleukin-6 (IL-6) were determined.

resultsPlasma (80.7 ± 37.3 pg/mL) and dialysate (33.2 ± 18.0 pg/mL) concentrations of copeptin were correlated (Rs = 0.52, p = 0.001). Plasma and dialysate copeptin concentrations were negatively correlated with renal function as assessed by renal Kt/V (Rs = - 0.38; p = 0.021 and Rs = - 0.33; p = 0.047, respectively). At PET, dialysate copeptin negatively correlated with D/P creatinine (Rs = - 0.35, p = 0.033), and positively with D/D0 glucose (Rs = 0.33, p = 0.045) and ultrafiltration (Rs = 0.37, p = 0.024). Multivariate analysis showed that low dialysate copeptin (β = -0.30, p = 0.049) and high dialysate IL-6 (β = + 0.40, p = 0.012) were independent determinants of higher D/P creatinine.

conclusionsDialysate copeptin was negatively associated with D/P creatinine in incident PD patients suggesting a potential influence of copeptin or AVP on peritoneal solute transport rate that might involve vasoactive mechanisms.

Indexed as

Peritoneal DialysisAdultCross-Sectional StudiesDialysis SolutionsFemaleGlycopeptidesHumansKidney Failure, ChronicMaleMiddle AgedPeritoneumcopeptinsDialysis SolutionsGlycopeptidesChronic kidney diseaseCopeptinPeritoneal dialysisSolute transport

Identifiers

PMID31187425
PMCPMC6713692
OpenAlexW2950263072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.